BUSINESS INSIGHTS, PHARMA TECH
Epredia | January 19, 2023
On January 18, 2023, PHC Group, a healthcare company renowned in diagnostics and life sciences, announced that it would join the RegeneratOR Innovation Accelerator to grow its presence in regenerative medicine. The Wake Forest Institute for Regenerative Medicine (WFIRM) and the RegenMed Development Organization (ReMDO) are the two institutions expediting the discovery and translation of regenerative medicine therapeutics located in the Innovation Quarter.
PHC Group, being an early partner of ReMDO's RegeneratOR Test Bed, offered advanced tissue processing technologies as well as support to researchers for prototype and product development. In addition, another ReMDO program, the Innovation Accelerator, was formed to give space and support to companies with innovative or emerging regenerative medicine technologies.
PHC Group is now opening a local office within the Innovation Accelerator. Its holding companies and partners include Epredia, a precision cancer diagnostics company whose products are used by researchers and pathologists worldwide, and Aiforia, a medical software company that develops artificial intelligence software for image analysis in pathology. Aiforia's collection of preclinical and clinical pathology instruments is distributed globally by Epredia.
The firms work together to deliver slide imaging and AI-based solutions that enable researchers to investigate and extract information beyond the scope of human visual perception. Thus, clinical research, drug discovery, and translational studies with the goal of better understanding disease states are all linked together through diagnostic microscopic imaging and artificial intelligence.
PHC Group's presence, along with Epredia and Aiforia's superior technology assistance at the Innovation Accelerator, will also pave the path for RegeneratOR's newest initiative, the RegenMed Clinical Trials Catalyst.
As a part of Wake Forest University School of Medicine and the academic core of the newly merged Advocate Aurora Health and Atrium Health, the Catalyst will have access to 5.5 million patients, serving 67 hospitals in North Carolina, Wisconsin, South Carolina, Georgia, Alabama, and Illinois.
About Epredia
Epredia is a leading comprehensive laboratory solutions provider for instruments and consumables in anatomic pathology, histology, and cytology. It was established through an acquisition by PHC Group from Thermo Fisher Scientific. The company provides solutions for cancer diagnostics through its renowned brands: Richard Allen Scientific, Erie Scientific, Microm, Shandon, and Menzel-Glaser. Epredia is committed to realizing its aim of advancing cancer diagnostics for patients worldwide in order to save lives.
Read More
BUSINESS INSIGHTS, PHARMACY MARKET
Shields Health Solutions | January 12, 2023
Shields Health Solutions (ShieldsRx), one of the leading specialty pharmacy accelerators, informed that the company has now collaborated with more than 850 hospitals at over 75 health systems after adding four more health systems.
ShieldsRx health system partners are well-positioned to improve therapy management and care coordination for critical patients, improving outcomes through high-quality care. Its health systems serve 1 million patients in 44 states.
Matt Conway, Chief Commercial Growth Officer of ShieldsRx stated, "As the foremost expert in health system specialty pharmacy, Shields has proven successful in partnering with health system leaders to develop integrated programs that deliver superior experiences and outcomes for complex patients." He further stated, "Not only do these programs deliver measurable clinical results but integrating specialty pharmacy within the health system also creates the net operating income health systems need to succeed. These proven clinical and financial results are why so many leading health systems trust Shields to elevate access, outcomes and growth within specialty pharmacy."
(Source- PRNewswire)
ShieldsRx's expansion with new health system partnerships includes
MyMichigan Health: Midland-based MyMichigan Health serves 25 counties. Its urgent care, home health, virtual care, and medical offices offer a broad spectrum of care in over 30 specialties and subspecialties.
Nemours Children's Health: Nemours Children's Health, the nation's most extensive multistate pediatric health system, has two free-standing children's hospitals and over 70 general and specialized care practices.
Solution Health: Phoenix Children's Care Network, Arizona's leading children's hospital, offers over 1,175 pediatric primary care professionals and specialists in over 75 subspecialties.
Traditional specialty pharmacy patients had to tackle administrative difficulties like prior authorization and expensive medical bills alone. Shields' expansion facilitated value-based reimbursement.
About Shields Health Solutions
Shields Health Solutions is a leading specialized pharmacy accelerator. Its Performance Platform is designed to improve payer and drug access for specialty pharmacies, improve health outcomes for complex patients, and promote growth across the entire health system. The company has access to over 80% of limited distribution medications (LDDs) and major health insurance payers in the U.S. along with a clinical strategy that lowers the total cost of treatment by 13%. ShieldsRx has collaborated with more than 70 health systems to deliver measurable clinical and financial benefits.
Read More
BUSINESS INSIGHTS, PHARMACY MARKET
Businesswire | March 27, 2023
Massive Bio, Inc., a private AI-enabled oncology startup that provides virtual and in-person concierge services for cancer patients, and NeoGenomics, Inc. a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced a collaboration with the goal of accelerating the development of new cancer therapies and ultimately improving the lives of millions of cancer patients around the world. NeoGenomics will identify patients in real time who may be eligible for clinical trials based on biomarker status. Following initial contact and outreach provided directly from NeoGenomics to the treating physician, Massive Bio will help obtain patient consent and expediate additional screening and potential enrollment. This partnership will help to quickly identify patients eligible for clinical trials and help patients and providers make an informed decision regarding their potential treatment avenue.
By combining their respective strengths in biomarker testing, data analysis, machine learning, and biomarker and genomic profiling, the collaboration between NeoGenomics and Massive Bio have achieved a significant milestone in the oncology industry.
"Our mission at Massive Bio is to provide cancer patients with the best possible care and treatment options,” said Selin Kurnaz, PhD, CEO and co-founder of Massive Bio. “By partnering with NeoGenomics, a leading player in the cancer diagnostics industry that shares Massive Bio’s commitment to advancing cancer research and improving patient outcomes, we can leverage their expertise in oncology diagnostics to accelerate the identification of patients who may be eligible for clinical trials."
“NeoGenomics’ advanced diagnostic tools and U.S. footprint, combined with Massive Bio's AI capabilities and concierge services in oncology, will enable us to match patients to clinical trials faster and more efficiently, resulting in improved outcomes and reduced costs,” said Vishal Sikri, President of the Advanced Diagnostics Division of NeoGenomics. “We are thrilled to partner with Massive Bio to advance precision medicine and improve the delivery of healthcare services to patients, pharmaceutical partners, and healthcare providers."
Dr. Arturo Loaiza-Bonilla, MD, co-founder and Chief Medical Officer of Massive Bio, added, "This collaboration between NeoGenomics and Massive Bio will enable us to provide patients with personalized care and support throughout their cancer journey, and move the needle forward in precision oncology and research."
AboutMassive Bio
Massive Bio empowers cancer patients to find their best treatment options, using artificial intelligence to improve equitable access and precision targeting for clinical trial matching, drug matching, and drug development. Massive Bio combines its best-in-class AI platform with technology-enabled services to remove barriers in clinical trial enrollment, value-based oncology decisions, and data-driven cancer treatment. The company serves more than two dozen pharmaceutical companies, contract research organizations, and hospital networks, and has been awarded an SBIR contract by the National Cancer Institute. Massive Bio was founded in 2015 by clinical, technology, and M&A executives, and has a global presence with nearly 100 people in 12 countries.
Read More